29 results about "Injury brain" patented technology

The application discloses a new use of Leonurine or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating radiation-induced brain injury, specifically, providing a safe and effective therapeutic drug for iron death, neuroinflammation, neuron damage and lipid metabolism disorder accompanying the radiation-induced brain injury, solving the technical problem of lack of specific treatment means in the prior art, and having a wide clinical application prospect. Experiments adopt a C57BL / c mouse 30 Gy whole brain X-ray radiation model, and results show that Leonurine can significantly improve the body weight decrease and survival rate of the model mice, reduce the serum IL-6 and IFN-alpha levels, inhibit the activation of microglial cells in the cerebral cortex and hippocampus, protect and repair damaged neurons, and improve the ultrastructure of mitochondria and synapses; meanwhile, the expression of GPX4 and SLC7A11 proteins in the brain tissue is up-regulated, the GSH content is increased to inhibit iron death, and the levels of GPE, GPS and GPC related to lipid metabolism are restored.

A system for component testing for head or brain injury criteria can include a vehicle seat that is substantially stationary. A dummy can be seated in the vehicle seat. The dummy can include a head and a body. An impactor can be substantially aligned with the head. An airbag can be located between the dummy and the impactor. The impactor can be caused to be projected toward a head of a dummy at a target energy, a target position, and / or with a target stroke.

The application discloses a nano guanido drug system and a preparation method and application thereof, and relates to the technical field of medicine, in particular to a GCOF DHM @CAQK platform, can efficiently deliver drugs to a TBI injury site, can accumulate in a TBI brain injury area, can inhibit neuroinflammation, oxidative stress and protect neuron cells after TBI, can precisely intervene in secondary injury of TBI, and provides a new strategy for improving the prognosis of patients.

The present invention relates to a pharmaceutical composition comprising a pharmaceutically acceptable vehicle and non-pungent derivatives of capsaicin, in their tautomeric forms and pharmaceutically acceptable salts, as the sole active ingredient, for use in the stimulation of the sphenopalatine ganglion and the enhancement of cerebral blood flow, to prevent or reduce brain injury resulting from decreased cerebral blood flow. The composition is administered via the oral transmucosal route, preferably in the form of a mucoadhesive tablet, and may be formulated for immediate or prolonged release, ensuring effective and tolerable absorption while avoiding the irritant effects associated with pungent capsaicin.

This invention relates to the use of 5α-androsta-3β,5,6β-triol and its derivatives in the prevention or treatment of radiation-induced brain injury, and to methods for preventing or treating radiation-induced brain injury with 5α-androsta-3β,5,6β-triol and its derivatives.

The application discloses a carrier for engineering miR-124-3p The application discloses an application of an exosome hydrogel in preparation of a drug for treating traumatic brain injury, and belongs to the technical field of biological carrier drug delivery. miR-124- 3p The exosome vesicle structure can improve the stability of the miRNA in the body and the delivery efficiency of the miRNA into nerve cells, thereby enhancing the bioavailability. The engineering exosome is embedded in the QCC / OHM hydrogel system, so that the engineering exosome forms a stable delivery platform at the injury site, realizes sustained release and local enrichment of the exosome. The hydrogel material has good tissue adaptability, can enter irregular brain injury interstitial spaces through minimally invasive injection and form a scaffold structure, and provides a favorable microenvironment for nerve repair. The application can overcome the problems of poor stability of treatment molecules, short local retention time and difficulty in realizing multi-mechanism synergistic treatment, and provides a new technical scheme for treatment of traumatic brain injury.

The present invention relates to haptoglobin (Hp), and optionally hemopexin (Hx), for use in the treatment of traumatic brain injury (TBI) and in particular in the treatment or prevention of a secondary brain injury in a subject suffering from a TBI.

The application discloses application of a MAC-1 agonist in preparation of a medicine for treating and / or relieving cerebral hemorrhage. Specifically disclosed is the use of Leukadherin-1 (LA-1) or a pharmaceutically acceptable salt, isomer or derivative thereof in preparation of a medicine for treating cerebral hemorrhage and secondary brain injury thereof. The medicine can inhibit the migration of immune cells across the blood-brain barrier, reduce cerebral edema, promote hematoma absorption and reduce neural inflammation by regulating the MAC-1-mediated immune adhesion signal pathway, thereby exerting a neuroprotective effect. Meanwhile, a pharmaceutical composition containing the MAC-1 agonist is provided. The application provides a new target and a drug development strategy for cerebral hemorrhage treatment.

Provided are: a therapeutic and / or prophylactic agent for at least one type of epilepsy selected from the group consisting of epilepsy after brain injury and epilepsy after the formation of compensatory brain areas; and a pharmaceutical composition containing the same.　This therapeutic and / or prophylactic agent for epilepsy after brain injury comprises a compound represented by general formula (1) or a salt thereof. (R1 and R2 are the same or different and represent one or more groups selected from a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, an optionally substituted aryl group, an optionally substituted C1-6 alkoxy group, an optionally substituted aryloxy group, an optionally substituted C1-6 alkylthio group, an optionally substituted arylthio group, an optionally substituted C2-6 alkenyl group, an optionally substituted C2-6 alkenyloxy group, an optionally substituted C1-6 alkylamino group, an optionally substituted C1-6 alkylsulfonyl group, an optionally substituted arylsulfonyl group, an optionally substituted carbamoyl group, an optionally substituted heterocyclic group, an optionally protected amino group, an optionally protected hydroxyl group, an optionally protected carboxyl group, a nitro group, and an oxo group; R3 represents an optionally substituted C1-6 alkylamino group, an optionally protected amino group, or an optionally protected hydroxyl group; and m and n are the same or different and each represent an integer of 1-6.)

The present disclosure relates to a mobile state electrode screening method, device, equipment and computer readable storage medium. Relates to the field of computer technology, including through the band-pass filter to the target electroencephalogram signal is accurate division get multiple preset frequency band, and combined with the relative power calculation realizes feature normalization, overcomes the defect that the traditional method is not enough to protect the subtle electroencephalogram feature. Secondly, based on the relative power data statistics index of normal user and abnormal user is calculated, and the variation coefficient double verification mechanism is introduced, when the statistical index is less than the first threshold value and the variation coefficient is less than the second threshold value, the target electrode is confirmed, this kind of comprehensive screening standard based on statistical significance and feature stability ensures that the electrode has both discriminant ability and robustness. Through this targeted screening mechanism, the electrode redundancy is significantly reduced, which can focus on the electrodes that are really effective for brain injury classification, so as to realize high-precision classification in mobile environment and optimize the calculation efficiency.

This invention discloses the application of induced pluripotent stem cell (EPC) derived from induced pluripotent stem cell differentiation in the preparation of stroke therapeutic agents. Through intravenous injection of EPCs into an animal model of stroke, this invention demonstrates that this method can treat stroke by inhibiting atherosclerosis, reducing cerebral infarction levels, promoting angiogenesis in lesioned brain tissue, improving inflammatory responses in lesioned brain tissue, and repairing nerve damage and brain injury. The above research results of this invention provide a new treatment method for stroke in clinical practice.

This invention belongs to the field of pharmaceutical technology and relates to an iron-tea polyphenol coordination polymer nanoparticle, its preparation method, and its application. The application of nanotechnology in the medical field is rapidly developing. Nanomaterials, as potential "smart" drugs, can enhance therapeutic effects through targeted drug release. Although research on nanomaterials is promising, the challenge of ineffective drug treatment in the brain, especially in the treatment of radiation-induced brain injury, still needs to be overcome. Therefore, developing novel nanomaterials, particularly those with neuroprotective effects, and further elucidating their neuroprotective effects, will provide new possibilities for the treatment of radiation-induced brain injury. This invention provides a novel iron-tea polyphenol (Fe-TP) coordinated nanomaterial that utilizes the coordination properties of Fe-TP to mitigate adverse reactions caused by radiation damage, thereby addressing the serious health problems caused by radiation-induced brain injury.

The present application provides a central nervous system targeting pharmaceutical composition which can be used to treat various brain injury patterns, by genetically engineering an integrin antibody to bind to a transmembrane protein of an exosome, and coating the exosome as a carrier with a therapeutic drug.

This invention discloses an adaptive drug delivery system for ischemic stroke, its preparation method, and its application. MMP-2 responsive peptide-drug dimers are loaded onto the surface of mesoporous polydopamine for intervention or treatment of cerebral ischemia-reperfusion injury. The system allows for targeted drug delivery based on individual differences in disease progression among patients, precisely promoting brain injury repair. This invention applies MMP-2 responsive peptides to the treatment of ischemic stroke, using mesoporous polydopamine as a drug carrier, providing reactive sites and loading space for efficient drug loading. The chemical reaction between catechol on the polydopamine surface and the thiol groups on the MMP-2 responsive peptides loads the peptide-drug dimers, thereby achieving responsive drug release on the carrier surface. Simultaneously, this invention utilizes the ability of polydopamine to scavenge reactive oxygen species (ROS), rapidly clearing local ROS and reducing acute damage caused by ischemic stroke.

Methods of diagnosing, monitoring, treating, and predicting the course of traumatic brain injury (TBI), including mild traumatic brain injury (mTBI), include determining a level of at least one RNA biomarker (e.g., miRNA) in a saliva sample from a subject. Also described are sensor elements, detection systems, compositions, and kits for diagnosing, monitoring, treating, and predicting the course of TBI.

An injectable, self-healing hydrogel, its preparation method, and its applications. This invention belongs to the field of biomedical engineering and neural regeneration, specifically relating to a hydrogel, its preparation method, and its applications. This invention provides an injectable, self-healing hydrogel for carrying neural stem cells based on Schiff base crosslinking. This hydrogel achieves self-healing and injectability through dynamic Schiff base bonds. A reversible imine bond crosslinking structure is formed through the Schiff base reaction between amino and aldehyde groups, exhibiting good biocompatibility and structural stability. The surface of biological tissue is rich in amino and hydroxyl groups, which can react again with the aldehyde groups in the OHA to form a dynamic covalent crosslinking network. Through interfacial Schiff base bonding, electrostatic attraction, and hydrogen bonding, this hydrogel can achieve strong wet adhesion to biological tissue and form a stable scaffold at the site of brain injury. Simultaneously, the nanospheres in the system can achieve sustained release of growth factors, effectively promoting the survival, proliferation, and differentiation of neural stem cells, ultimately achieving precise repair and functional recovery of neural tissue.

The application discloses application of glycyrrhiza chalcone D in preparation of a drug for treating spontaneous cerebral hemorrhage and belongs to the technical field of biological medicine. The application provides application of glycyrrhiza chalcone D in preparation of a drug for treating and improving prognosis of spontaneous cerebral hemorrhage. Rat experiment results show that glycyrrhiza chalcone D can reduce hematoma of cerebral hemorrhage, reduce death of nerve cells after hemorrhage and reduce levels of inflammatory factors; cell experiment results show that glycyrrhiza chalcone D can be used as an inhibitor of ferroptosis and a COX2 inhibitor, improve ischemia and hypoxia injury of nerve cells after spontaneous cerebral hemorrhage and has a better effect than a commonly used ferroptosis inhibitor Fer-1. The application firstly reports that glycyrrhiza chalcone D is used for treating spontaneous cerebral hemorrhage and improving secondary brain injury, provides a new scheme for treatment of spontaneous cerebral hemorrhage and has a good clinical drug application prospect.

This invention provides a method, device, terminal, and medium for assistive training in the rehabilitation of spasticity after brain injury. The method includes: acquiring surface electromyography (EMG) signals and the start time of postural transition; obtaining average amplitude, maximum voluntary contraction amplitude, left-right symmetry index, stability index, and pre-activation time; obtaining a core muscle group function score based on the calculated average amplitude, maximum voluntary contraction amplitude, left-right symmetry index, stability index, and pre-activation time; determining the patient's training position, training goals, training mode, initial treatment parameters, and treatment optimization goals; guiding the patient in adaptive rehabilitation training, collecting surface EMG signals of the patient's core muscle groups in real time, dynamically adjusting stimulation parameters through an adaptive prediction model and the surface EMG signals, and completing the assistive rehabilitation training for spasticity after brain injury after the adaptive prediction model converges. This reduces reliance on the therapist's subjective experience and achieves precise rehabilitation training.

This invention belongs to the field of medicine, specifically relating to a nanomedicine targeting the central cortex for the treatment of brain injury and its application. The nanomedicine comprises a liposome shell formed of lipid material, and internally loaded with small interfering RNA, nucleic acid transfection-promoting materials, and anti-inflammatory drugs; the lipid material includes phospholipid materials and lipid excipients. The outer layer of the nanomedicine is modified with positively charged blood-brain barrier permeable material vascular endothelial growth factor (VEGF) through electrostatic adsorption. This invention utilizes the central targeting properties of lipid nanoparticles and VEGF to achieve highly efficient targeted delivery of the nanomedicine to the cerebral cortex region, delivering a series of repair-promoting drug components to the highly vulnerable cerebral cortex region, thereby improving the treatment effect of brain injury. This invention also relates to the preparation method and uses of this nanomedicine.

A compound of formula (I), for use in the treatment of non-traumatic acquired brain injury,in which M represents a NR1R2 group, an OR1 group or a SR1 group, A represents a NR4R5 group, an OR10 group or a hydrogen atom, R3 is a (C1-C6)alkyl group, a (C1-C6)cycloalkyl group, an aryl group, a —CH2-aryl group, a CH2-(C1-C6)cycloalkyl group or a —CH2-heteroaryl group, and its addition salts with pharmaceutically acceptable acids. A compound of formula (I) wherein R5 is a (C1-C8)alkyl group or a (C1-C6)cycloalkyl group, said alkyl and cycloalkyl group being substituted with one, two or three —OCORa group(s).

This application discloses succinimide derivatives in the field of organic chemistry, with the general structural formula shown in Formula V. During preparation, compound I reacts with compound II to yield compound III; compound III reacts with compound IV in the presence of a condensing agent to yield succinimide derivative V. The succinimide derivatives of this application can be used in the preparation of sedative, tranquilizing, nootropic, anticonvulsant, antiepileptic, antineuralgia, anti-anxiety, antidepressant, antidementia, and / or brain injury protective drugs.

This application relates to the field of pharmaceutical use technology, disclosing the application of a pharmaceutical composition in the preparation of drugs for the prevention or treatment of chronic alcoholic brain injury, developing a new use for Tongrentang Niuhuang Qingxin Pills, providing new therapeutic drugs and methods for the intervention and treatment of chronic alcoholic brain injury, thereby providing technical support for the rational use of drugs. This application demonstrates the therapeutic effect of Tongrentang Niuhuang Qingxin Pills on alcoholic brain injury through experiments on model rats, including the detection of learning and memory abilities, balance ability indicators, pathological changes in brain tissue, and S100-β in cerebrospinal fluid.

The present invention relates to pharmaceutical compositions for oral administration of A3R agonist compounds. The compositions are designed to disintegrate or disperse rapidly to deliver an effective dose of the compound for treating, ameliorating, or promoting recovery from certain conditions of the brain, central nervous system (CNS), or cardiovascular system such as a brain injury, a neurodegenerative condition, or cardiac ischemia.

The present application relates to the technical field of medical equipment and artificial intelligence, and particularly relates to a brain disease data intelligent evaluation method and system for carbon monoxide poisoning. The brain disease data intelligent evaluation method for carbon monoxide poisoning comprises the following steps: S1: a dynamic data acquisition framework covering the whole cycle of the disease is designed, and core data at key time points after carbon monoxide poisoning is collected, wherein the core data comprises multi-modal image data, clinical evaluation data and laboratory data; S2: a time series data analysis engine is constructed, multi-modal image data collected is subjected to space-time registration through the time series data analysis engine, batch extraction of key brain region microstructure parameters is performed, and dynamic trajectory data of each parameter is calculated, wherein the dynamic trajectory data comprises a current value, a change rate and an evolution mode of the parameter. Through construction of a dynamic data acquisition and intelligent analysis system covering the whole cycle of the disease, the present application realizes evaluation of the evolution process of brain injury after poisoning.

The application provides a emodin-8-O-beta-D-glucoside / baicalein hydrogel and a preparation method and application thereof, and the preparation method comprises the following steps: dissolving baicalein in a PBS solution with a pH of 7-8 to obtain a baicalein solution; mixing emodin-8-O-beta-D-glucoside with the baicalein solution to obtain a mixed solution; and performing ultrasonic dispersion on the mixed solution at an ultrasonic power of 70 W-120 W and at 50 DEG C-70 DEG C to obtain the emodin-8-O-beta-D-glucoside / baicalein hydrogel. The emodin-8-O-beta-D-glucoside / baicalein hydrogel prepared by the method has the advantages that emodin-8-O-beta-D-glucoside and baicalein are directly self-assembled into a hydrogel without metal ions, organic polymers and organic solvents, and the hydrogel has obvious curative effect in the preparation of drugs for treating diseases such as post-brain injury neural function defect, blood-brain barrier injury and excessive activation of neutrophil extracellular traps.

The application discloses a method for constructing a microwave radiation animal brain injury model based on a medial septum-hippocampus CA3 cholinergic nerve loop regulation, comprising the following steps: setting electromagnetic radiation conditions, and performing electromagnetic radiation treatment on test animals; comparing whether a cholinergic nerve loop between the medial septum and the hippocampus CA3 is activated before and after the electromagnetic radiation treatment; and if the cholinergic nerve loop is activated, constructing an electromagnetic radiation animal brain injury model by using the electromagnetic radiation conditions. The application can accurately construct the electromagnetic radiation animal brain injury model, and increases the possibility of elucidating the molecular mechanism of the electromagnetic radiation brain injury effect and the research and development of prevention and treatment drugs.

This invention relates to the field of pharmaceutical technology, specifically to a perioperative neuroprotective anesthetic composition and its application for ischemic stroke. The composition comprises the active ingredient remimazolam or a pharmaceutically acceptable salt thereof, MCC950, TRO19622, levamisole or a pharmaceutically acceptable salt thereof, lipoic acid, and a pharmaceutically acceptable carrier, with each active ingredient formulated in a specific molar ratio. This composition combines stable and controllable anesthetic effects with multi-target synergistic neuroprotective effects, adapting to the entire perioperative anesthesia needs for ischemic stroke. Through upstream and downstream synergistic inhibition of mitochondrial damage and the NLRP3 pyroptosis pathway, dual regulation of perioperative sympathetic tone to stabilize cerebral perfusion, synergistic reduction of glutamate excitotoxicity, and enhancement of endogenous antioxidant defense, it comprehensively blocks the core links of perioperative ischemia-reperfusion brain injury, significantly reducing the risk of postoperative neurological deficits and cognitive impairment. It exhibits excellent circulatory and respiratory safety, rapid awakening without affecting early postoperative neurological function assessment.